Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESPONDER: Pembrolizumab in Advanced Urothelial Cancer
NCT03263039Phase 2Unknown
- Sponsor
- Erasmus MC
- Start
- Aug 2017
- Primary completion
- Aug 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in urothelial carcinoma (UC), sponsored by Erasmus MC. Primary endpoint: Biomarkers in patients with clinical benefit up to 24 months. Status: unknown.
02
Drugs
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03263039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03263039.